Osmotica Pharmaceuticals plc to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Osmotica Pharmaceuticals (Nasdaq: OSMT) announced that CEO Brian Markison and COO James Schaub will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Osmotica Pharmaceuticals (Nasdaq: OSMT) announced that CEO Brian Markison and COO James Schaub will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021. The presentation will be available on demand and can be accessed through a webcast link provided in the announcement. Osmotica specializes in developing products for underserved markets and launched UPNEEQ for treating droopy eyelids in September 2020. The webcast will be archived for 30 days on the company's website.
Details
News Market Reaction – OSMT
The recorded move for OSMT in the trading session of this news was +0.83%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRIDGEWATER, N.J., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and James “JD” Schaub, Chief Operating Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference as follows:
| Date: | Monday, September 13, 2021 |
| Time: | On Demand |
| Webcast: | https://journey.ct.events/view/2feb327a-ca2a-4226-806e-84a8a49480db |
The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.osmotica.com under the “Investor & News” section.
About Osmotica Pharmaceuticals plc
Osmotica Pharmaceuticals plc (Nasdaq: OSMT), together with its subsidiaries, is a specialty pharmaceutical company focused on the commercialization and development of products that target markets with underserved patient populations. In July 2020, the Company received regulatory approval from the U.S Food and Drug Administration for RVL-1201, or UPNEEQ® (oxymetazoline hydrocholoride ophthalmic solution),
Investor and Media Relations for Osmotica Pharmaceuticals plc
Lisa M. Wilson
In-Site Communications, Inc.
T: 212-452-2793
E: lwilson@insitecony.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.